BR112022013643A2 - Composto de tetra-hidroisoquinolina como modulador de canal de potássio e preparação e aplicação do mesmo - Google Patents

Composto de tetra-hidroisoquinolina como modulador de canal de potássio e preparação e aplicação do mesmo

Info

Publication number
BR112022013643A2
BR112022013643A2 BR112022013643A BR112022013643A BR112022013643A2 BR 112022013643 A2 BR112022013643 A2 BR 112022013643A2 BR 112022013643 A BR112022013643 A BR 112022013643A BR 112022013643 A BR112022013643 A BR 112022013643A BR 112022013643 A2 BR112022013643 A2 BR 112022013643A2
Authority
BR
Brazil
Prior art keywords
preparation
application
potassium channel
channel modulator
tetrahydroisoquinoline compound
Prior art date
Application number
BR112022013643A
Other languages
English (en)
Inventor
Liang Bo
Liu Gang
Chen Huanming
Original Assignee
Shanghai Zhimeng Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zhimeng Biopharma Inc filed Critical Shanghai Zhimeng Biopharma Inc
Publication of BR112022013643A2 publication Critical patent/BR112022013643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO DE TETRA-HIDROISOQUINOLINA COMO MODULADOR DE CANAL DE POTÁSSIO E PREPARAÇÃO E APLICAÇÃO DO MESMO. Um composto de tetra-hidroisoquinolina como um modulador de canal de potássio e preparação e aplicação do mesmo. Especificamente, o composto tem a estrutura como apresentada na fórmula A.
BR112022013643A 2020-08-07 2021-08-05 Composto de tetra-hidroisoquinolina como modulador de canal de potássio e preparação e aplicação do mesmo BR112022013643A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010790306.7A CN114057641A (zh) 2020-08-07 2020-08-07 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
PCT/CN2021/110991 WO2022028548A1 (zh) 2020-08-07 2021-08-05 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用

Publications (1)

Publication Number Publication Date
BR112022013643A2 true BR112022013643A2 (pt) 2022-12-13

Family

ID=80117052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013643A BR112022013643A2 (pt) 2020-08-07 2021-08-05 Composto de tetra-hidroisoquinolina como modulador de canal de potássio e preparação e aplicação do mesmo

Country Status (10)

Country Link
US (1) US20230077155A1 (pt)
EP (1) EP4071138A4 (pt)
JP (1) JP7458670B2 (pt)
KR (1) KR20220116466A (pt)
CN (2) CN114057641A (pt)
AU (1) AU2021319662B2 (pt)
BR (1) BR112022013643A2 (pt)
CA (1) CA3163938A1 (pt)
IL (1) IL294637A (pt)
WO (1) WO2022028548A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114057641A (zh) * 2020-08-07 2022-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
CN116535354A (zh) * 2022-01-25 2023-08-04 上海挚盟医药科技有限公司 作为钾通道调节剂的芳环并杂环类化合物及其制备和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661462C (en) 2006-08-23 2015-09-29 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
JP2010511052A (ja) * 2006-11-28 2010-04-08 バレアント ファーマシューティカルズ インターナショナル カリウムチャネル調節因子としての１，４ジアミノ二環式レチガビンアナログ
US8058274B2 (en) 2007-08-17 2011-11-15 Icagen, Inc. Heterocycles as potassium channel modulators
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
MX2017005719A (es) * 2014-11-03 2017-12-07 Iomet Pharma Ltd Compuesto farmaceutico.
CN107814785B (zh) * 2016-09-14 2021-02-05 四川大学 雄激素受体拮抗剂及其制备方法和用途
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN114057641A (zh) * 2020-08-07 2022-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用

Also Published As

Publication number Publication date
EP4071138A1 (en) 2022-10-12
AU2021319662A1 (en) 2022-07-14
CN114845995A (zh) 2022-08-02
CA3163938A1 (en) 2022-02-10
CN114057641A (zh) 2022-02-18
IL294637A (en) 2022-09-01
JP2023510233A (ja) 2023-03-13
JP7458670B2 (ja) 2024-04-01
WO2022028548A1 (zh) 2022-02-10
CN114845995B (zh) 2024-02-13
EP4071138A4 (en) 2023-07-19
US20230077155A1 (en) 2023-03-09
KR20220116466A (ko) 2022-08-23
AU2021319662B2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
CL2020000596S1 (es) Auriculares.
BR112022013643A2 (pt) Composto de tetra-hidroisoquinolina como modulador de canal de potássio e preparação e aplicação do mesmo
TWD201829S (zh) 無柵線太陽能電池
MX2016001424A (es) Composiciones edulcorantes.
CL2023001550A1 (es) Sistemas activos dinámicos acromosómicos.
CL2016000106A1 (es) Sulfonamidas como moduladores de canales de sodio.
EA201591474A1 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
UA107791C2 (en) Pesticidal compositions
UY31274A1 (es) Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
TR201907828T4 (tr) Geni̇ş spektrumlu bi̇r anti̇-mi̇krobi̇yel ajan
CR20170111A (es) Derivados de benzodiazepina citotóxicos
MX352563B (es) Composiciones para el cuidado oral que contienen carbonato de calcio y silice.
MX2018008441A (es) Glicosidos de esteviol altamente solubles.
TWD201820S (zh) 無柵線太陽能電池
AR104488A1 (es) Alcoxilatos de alcohol de intervalo estrecho y derivados de estos
AR109409A1 (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso
MX2016003543A (es) Estructuras fibrosas mejoradas que contienen surfactantes y metodos para fabricarlas.
MX2021003723A (es) Composiciones antimicrobianas que contienen n-alquil gamma butirolactama de c3-c5 y usos de las mismas.
CL2019001469S1 (es) Cepillo de dientes.
BR112017018707A2 (pt) composições compreendendo compostos de mentol como agentes suavizantes
CL2019001470S1 (es) Cepillo de dientes.
AU2017256125A1 (en) Oral composition
CR8876A (es) 1,1,2,2-tetra(hetero)ariletanos 1,1,2-tri(hetero)-aril-2-heterocicloetanos como inhibidores de canales de potasio
MX2020013072A (es) Composicion anticontaminacion.